Protagonist Therapeutics (PTGX) Tops Q3 EPS by 1c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.62), $0.01 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.71 million versus the consensus estimate of $4.51 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• argenx SE (ARGX) PT Raised to $1,200 at Citizens on VYVGART Indication Expansion
• XP Inc. (XP) Tops Q2 EPS by 8c